Primary Sclerosing Cholangitis
Investigators
Open Research Studies for Primary Sclerosing Cholangitis
Gilead PSC (P2 & P3)
Enrolling: Yes
Principle Investigator: Raj Vuppalanchi, MD
Duration: P3 - 110 weeks
Patient Population: Non-cirrhotic large duct PSC
Drug(s): Oral GS9674 (Cilofexor)
Interested in this study? Please contact the coordinator below:
Mandy Cruz
mandcruz@iu.edu
(317) 278-6215
Mayo RC2
Enrolling: Yes
Principle Investigator: Craig Lammert, MD
Duration: 1 visit
Patient Population: PSC with at least 6 month biochemical presence of chronic cholangitis, must not have NASH.
Interested in this study? Please contact the coordinator below:
Kelsey Green
greenke@iu.edu
(317) 278-9292
Pliant
Enrolling: Yes
Principle Investigator: Raj Vuppalanchi, MD
Duration: 12 week study period
Patient Population: PSC patients without cirrhosis.
Drug(s): PLN-74809 Oral
Interested in this study? Please contact the coordinator below:
Mandy Cruz
mandcruz@iu.edu
(317) 278-6215
Progress PSC
Enrolling: Yes
Principle Investigator: Craig Lammert, MD
Duration: 1 visit.
Patient Population: Patients with PSC with ERCP, MRCP or liver biopsy.
Interested in this study? Please contact the coordinator below:
Kelsey Green
greenke@iu.edu
(317) 278-9292
Closed Primary Sclerosing Cholangitis Studies
-
PSC CALiD
Enrolling: No
Principle Investigator: Craig Lammert, MD
Duration: 1 visit per year over 20 years
Patient Population: Patient population is PSC/pre-transplant with no history concomitant liver disease.